|
|
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
||||||||||||||||||||||||||||||||||||
| Sponsored by: |
Nanjing Medical University |
| Information provided by: | Nanjing Medical University |
| ClinicalTrials.gov Identifier: | NCT00647725 |
Purpose
Painless labor is an essential part in woman's health care. Labor analgesia in the active phrase is in popular use currently. However, parturients are still haunted by the labor delivery pain in the latent phrase up to 7-8 hours, especially for the nulliparas. Therefore, we hypothesized that labor analgesia in the latent phrase of the first delivery stage would provide superior health care for laboring women. In addition, such analgesia technique would not prolong the time of uterine dilation and labor delivering.
| Condition | Intervention |
|
Labor Pain |
Procedure: Active phrase epidural analgesia Procedure: Latent phrase epidural analgesia |
| ChemIDplus related topics: | Sufentanil Sufentanil citrate Ropivacaine Ropivacaine Hydrochloride Ropivacaine monohydrochloride |
| Study Type: | Interventional |
| Study Design: | Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Safety/Efficacy Study |
| Official Title: | Labor Analgesia in the Latent Phrase of the First-Stage of Spontaneous Delivery |
| Enrollment: | 15000 |
| Study Start Date: | January 2003 |
| Study Completion Date: | December 2007 |
| Primary Completion Date: | December 2007 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|
I: Active Comparator
Active phrase analgesia
|
Procedure: Active phrase epidural analgesia
Continuous epidural analgesia with sufentanil plus ropivacaine
|
|
II: Active Comparator
Latent phrase analgesia
|
Procedure: Latent phrase epidural analgesia
Continuous epidural analgesia with sufentanil plus ropivacaine
|
Eligibility
| Ages Eligible for Study: | 18 Years to 45 Years |
| Genders Eligible for Study: | Female |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contacts and Locations| China, Jiangsu | |||||
| Nanjing Maternal and Child Health Care Hospital | |||||
| Nanjing, Jiangsu, China, 210004 | |||||
| Nanjing Medical University |
| Study Director: | XiaoFeng Shen, MD | Nanjing Medical University |
More Information
| Responsible Party: | Nanjing Medical University ( XiaoFeng Shen ) |
| Study ID Numbers: | NMU-69714-14XS, MCH03552 |
| First Received: | March 28, 2008 |
| Last Updated: | March 31, 2008 |
| ClinicalTrials.gov Identifier: | NCT00647725 |
| Health Authority: | China: Ethics Committee |
|
|
|
|